Table 2 Clinical outcomes of all CAEBV patients post HSCT.
Patient | aGVHD location# | cGVHD location$ | Early complications | Early infections | Viral reactivation | Survival | Cause of death |
|---|---|---|---|---|---|---|---|
PTCy-1 | None | None | HC, RPLC | Sepsis, urinary system infection (bacteria) | CMV | Dead | Diffuse alveolar hemorrhage |
PTCy-2 | Intestine (II) | None | Immunologic lung injury | CMV retinitis | CMV | Alive | – |
PTCy-3 | None | Digestive tract (M) | None | None | EBV | Alive | – |
PTCy-4 | None | None | None | None | CMV | Alive | – |
PTCy-6 | None | None | None | None | None | Alive | – |
PTCy-7 | None | None | ES, PGF | CMV retinitis | CMV | Alive | – |
PTCy-8 | None | Lung (M) | Drug-induced seizure | None | CMV, EBV | Alive | – |
PTCy-9 | None | None | None | None | CMV | Alive | – |